<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278718</url>
  </required_header>
  <id_info>
    <org_study_id>MW2012-01-01</org_study_id>
    <nct_id>NCT02278718</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care</brief_title>
  <official_title>A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GCP-Service International Ltd. &amp; Co. KG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a two-arms study intending to demonstrate superiority of NexoBrid
      treatment over SOC in children with thermal burns. The study objective is to evaluate the
      safety and clinical benefit of NexoBrid in hospitalized children (0-17 years) with deep
      partial and/or full thickness thermal burns of 1-30% TBSA and to compare NexoBrid to standard
      of care (SOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 160 patients will be randomized into NexoBrid and SOC treatment (80 patients per
      arm).

      Age distribution will be managed as follows:

        -  40 patients 0-23 months old

        -  40 patients 24 months-3 years old

        -  48 patients 4-11 years old

        -  32 patients 12-17 years old

      The study will be conducted in two stages. In Stage I, 50 children age 4-17 years,
      hospitalized in burn units, with deep partial thickness burns ranging from 1%-30% TBSA, and
      who meet the entrance criteria, will be enrolled. Upon completion of stage I (once the 50th
      patient has reached wound closure), an interim analysis will be performed on safety
      parameters and the results will be blindly evaluated by a Data Safety Monitoring Board
      (DSMB). If the DSMB does not have any safety concerns, Stage II will commence, this time
      enrolling children at the aged of 0-17 years according to the study procedures.

      Following the enrollment of a subject to the study and prior to randomization, physicians
      will define one or more Target Wounds (TWs) per subject according to TWs definition. All
      subjects' DPT and FT burns that fit the specified criteria are intended to receive study
      treatment per randomized study arm and therefore, must be designated as TWs.

      Prior to eschar removal treatment with NexoBrid or SOC subjects will be medicated with
      appropriate analgesia and undergo wound cleansing and dressing of all wounds with
      antibacterial solutions. Following wound cleansing and antibacterial treatments, subjects
      will undergo the eschar removal process as per treatment assignment (NexoBrid or SOC,
      following randomization). Subsequent to eschar removal, all wounds will be assessed and
      treated in the same manner, in accordance with post-eschar removal wound care strategy.
      Furthermore, subjects will undergo daily assessments (Vital signs (VS) and pain assessments)
      for one week and weekly assessments thereafter, until wound closure. Following wound closure,
      subjects will be followed up at 6 weeks, 12 weeks, and after that, at 6, 12, 18 and 24 months
      (for a blinded assessment of cosmesis, function and QoL evaluation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Earlier eschar removal (in days)</measure>
    <time_frame>participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Demonstrate superiority over SOC for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time. Eschar removal will be measured at the end of the debridement starting from randomization date.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Thermal Burns</condition>
  <arm_group>
    <arm_group_label>NexoBrid Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non surgical and Surgical Debridement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <arm_group_label>NexoBrid Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Stage 1: Males and females between 4 years to 17 years of age, Stage 2 (upon approval
             of DSMB): Males and females between 0 years to 17 years of age.

          2. Thermal burns caused by fire/flame, scalds or contact.

          3. Patient total burns area should be between 1% to 30% TBSA (≥ 1% and ≤ 30% ; SPT, DPT
             and/or FT in depth),

          4. Signed written informed consent by a legal guardian can be obtained within 72 hours of
             the burn injury.

        At least one wound (a continuous burn area which can be treated in one session; might
        include several anatomical areas) in a patient should meet all following criteria:

          1. Wound that is ≥ 1% TBSA (not including face, perineal or genital),

          2. Wound is composed of DPT and/or FT in depth. Superficial partial thickness areas may
             be included in the wound area only if cannot be separated from deeper areas (e.g.
             surrounded by or mixed with DPT areas) and might interfere with the treatment of the
             deeper areas,

          3. Wound that is intended for surgical eschar removal,

          4. Wound's blisters can be unroofed, as judged by the investigator.

        Exclusion Criteria:

          1. Patients who are unable to follow study procedures and follow up period,

          2. Patients with electrical or chemical burns,

          3. Patient with a continuous burn area above 15% TBSA,

          4. Patients with no DPT and/or FT burn area (only SPT wounds),

          5. DPT and/or FT facial burn wounds from flame, flash, explosion &gt;0.5% TBSA (scald and
             contact burns are allowed); study treatment of all facial burns is not allowed,

          6. Study treatment of perineal and/or genital burns is not allowed; however, a patient
             with these wounds may be enrolled but the wounds may not be designated as target
             wounds,

          7. Patient with circumferential anterior/posterior trunk fire/flame burns, &gt;15% TBSA
             (Circumferential is defined as encircling ≥ 80% of the trunk circumference),

          8. The following pre-enrolment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),

          9. Patients with diagnosed infections as described in Section 13.2.5 of study protocol,

         10. Any signs or history that may indicate smoke inhalation (e.g. flames in enclosed
             spaces, smoke and fumes on the patient and in mouth and nostrils, deep flame burns
             &gt;0.5 %TBSA to the face, cough, hoarseness, stridor or breathing difficulty including
             tachypnea possibly related to smoke inhalation, etc.),

         11. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with
             iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of SSD treatment),

         12. Patients with pre-enrolment escharotomy,

         13. Pregnant women (positive pregnancy test) or nursing mothers,

         14. Poorly controlled diabetes mellitus (HbA1c&gt;9%),

         15. Known Cardio-pulmonary disease, oxygen-dependent pulmonary diseases,
             broncho-pneumonia, steroid dependent asthma or uncontrolled asthma),

         16. Known conditions which interfere with circulation (peripheral vascular disease, edema,
             lymphedema, surgery to the regional lymph nodes, obesity),

         17. Any known conditions that would preclude safe participation in the study or add
             further risk to the basic acute burn trauma (such as immuno-compromising diseases,
             life threatening trauma, severe pre-existing coagulation disorder,
             pulmono-cardiovascular, liver or neoplastic disease),

         18. ASA greater than 2

         19. Chronic systemic steroid intake,

         20. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or
             papain,

         21. Current (within 12 months prior to screening) suicide attempt,prior to screening,

         22. Enrollment in any investigational drug trial within 4 weeks prior to screening,

         23. Current (within 12 months prior to screening) alcohol (daily consumption &gt; 3 units for
             males and &gt;2 units for females) or drug abuse,

         24. Prisoners and incarcerated

         25. Patients who might depend on the clinical study site or investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Rosenberg, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaron Shoham, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tami Aibester</last_name>
    <phone>+972-77-971-4168</phone>
    <email>tamia@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David-Zarbiv</last_name>
    <phone>+972-77-9714103</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Department of Plastic Surgery</name>
      <address>
        <city>Gent</city>
        <zip>B 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Stan J. Monstrey</last_name>
      <phone>0032-(0) 9-332 2220</phone>
      <email>stan.monstrey@UGENT.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHATEM N.I.Pirogov</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Prof. Ognyan Hadzhiyski</last_name>
      <phone>00359 2 9526690</phone>
      <email>burns_hadj@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin - Tripode</name>
      <address>
        <city>Bordeaux cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr. Vincent Casoli</last_name>
      <phone>00 33 (0)5 56 79 56 79</phone>
      <email>vincent.casoli@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Renaud Vialet</last_name>
      <phone>0033(0)4 91 96 86 68</phone>
      <email>renaud.vialet@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Plastique, Centre des Brûlés</name>
      <address>
        <city>Nantes cedex</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr. Franck Duteille</last_name>
      <phone>02 40 08 37 12</phone>
      <email>pierre.perrot@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Bernd Hartmann</last_name>
      <phone>030 5681 3501</phone>
      <email>bernd.hartmann@ukb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKK Altonaer Kinderkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>D- 22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. med. Ingo Königs</last_name>
      <phone>+49 40 88908- 230</phone>
      <email>ingo.koenigs@kinderkrankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Kinderchirurgie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Karl Bodenschatz</last_name>
    </contact>
    <contact_backup>
      <phone>0911 398-5455</phone>
      <email>karl.bodenschatz@klinikum-nuernberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Olgahospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Torsten Hannmann</last_name>
      <phone>+49 711 2787 3625</phone>
      <email>t.hanmann@klinikum-stuttgart.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Healthcare Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Prof.Yehuda Ullmann</last_name>
      <phone>+972-4-8542794</phone>
      <email>y_ullmann@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Giancarlo Delli Santi</last_name>
      <phone>+393203678544</phone>
      <email>gdsanti@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acute Burn Care &amp;Trauma Surgery, Dept Surgery/Burn Center, Rode Kruis Ziekenhuis, LUMC University Leiden</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Rolf Breederveld</last_name>
      <phone>0031 251 265555</phone>
      <email>rbreederveld@rkz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii, &quot;Grigore Alexandrescu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011743</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DR. Prof. Dan Mircea Enescu</last_name>
      <phone>+40744355511</phone>
      <email>enescudr@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgență pentru Copii</name>
      <address>
        <city>Cluj</city>
        <zip>400001</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Horatiu Gocan</last_name>
      <phone>+4 0744500525</phone>
      <email>horatiugocan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Sfanta Maria&quot;</name>
      <address>
        <city>Iasi</city>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Elena Hanganu</last_name>
      <phone>+4 0744709689</phone>
      <email>dr.elenahanganu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Tg- Mures</name>
      <address>
        <city>Tg-Mures</city>
        <zip>54000</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gheorghe Horea Gozar</last_name>
      <phone>+4 0740070534</phone>
      <email>horea_gozar@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timisoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DR. Sorin Eugen Boia</last_name>
      <phone>+4 0732890553</phone>
      <email>boiaeugen@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava, Klinika popálenin a rekonštrukčnej chirurgie</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ján Koller</last_name>
      <phone>+421(2)48234527</phone>
      <email>koller@ru.unb.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika popálenin a rekonštrukčnej chirurgie, Nemocnica Košice-Šaca a.s.</name>
      <address>
        <city>Košice-Šaca</city>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Prof. Peter Lengyel</last_name>
      <phone>00421911500551</phone>
      <email>plengyel@nemocnicasaca.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institut de Recerca (VHIR)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ricardo Palao</last_name>
      <phone>+34 629 33 01 02</phone>
      <email>rpalao@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Juan Carlos López Gutierrez</last_name>
      <phone>+34 639 20 38 67</phone>
      <email>queminfantil.hulp@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boulevar Sur s/n</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Patricia Gutierrez Ontalvilla</last_name>
      <phone>+34 669 88 49 28</phone>
      <email>patricia@dragutierrez.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aragonese Institute of Health Sciences</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Enrique Monclús Fuertes</last_name>
      <phone>+34 607 476 794</phone>
      <email>doctorenriquemonclus@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brännskadecentrum, VO Plastikkirurgi och Käkkirurgi, Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Fredrik Huss</last_name>
      <phone>+46 70 7941 574</phone>
      <email>fredrik.huss@akademiska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Victoria Hospital</name>
      <address>
        <city>East Grinstead</city>
        <state>West Sussex</state>
        <zip>RH19 3DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Baljit Dheansa</last_name>
      <phone>0044 1342 4140 24</phone>
      <email>Baljit.Dheansa@QVH.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children´s Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Yvonne Wilson</last_name>
      <phone>+44 121 333 8964</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=nexobrid</url>
  </link>
  <reference>
    <citation>Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014 May;40(3):466-74. doi: 10.1016/j.burns.2013.08.013. Epub 2013 Sep 26.</citation>
    <PMID>24074719</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

